Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

This early-stage study tested a new oral drug called TQB3909 in adults whose mantle cell lymphoma had returned or did not respond to prior treatments. The main goals were to find a safe dose for future testing and to closely monitor for any side effects. The trial was terminated …

This early-stage trial tested a new two-drug combination for people with advanced bone cancer (osteosarcoma) or other solid tumors that had returned or spread after standard treatments. The goal was to see if the combination could slow cancer growth and was safe. The study was te…